On Thursday, Smith & Nephew ADR earned a positive adjustment to its Relative Strength (RS) Rating, from 74 to 82.
Risk Management In The Stock Market: How Much Money To Invest Now
IBD's unique rating identifies market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the trailing 52 weeks holds up against all the other stocks in our database.
History reveals that the market's biggest winners tend to have an 80 or better RS Rating as they launch their biggest price moves.
Smith & Nephew ADR is trying to complete a consolidation with a 31.72 buy point. See if the stock can break out in heavy trading.
The company reported -2% earnings growth in the latest quarterly report. Sales increased 6%.
The company holds the No. 20 rank among its peers in the Medical-Products industry group. Pro-Dex, Penumbra and Boston Scientific are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
